Treatment of Retinoblastoma 1–Intact Hepatocellular Carcinoma With Cyclin‐Dependent Kinase 4/6 Inhibitor Combination Therapy

Background and Aims Synthetic cyclin‐dependent kinase (CDK) 4/6 inhibitors exert antitumor effects by forcing RB1 in unphosphorylated status, causing not only cell cycle arrest but also cellular senescence, apoptosis, and increased immunogenicity. These agents currently have an indication in advance...

Full description

Saved in:
Bibliographic Details
Published inHepatology (Baltimore, Md.) Vol. 74; no. 4; pp. 1971 - 1993
Main Authors Sheng, Jindan, Kohno, Susumu, Okada, Nobuhiro, Okahashi, Nobuyuki, Teranishi, Kana, Matsuda, Fumio, Shimizu, Hiroshi, Linn, Paing, Nagatani, Naoko, Yamamura, Minako, Harada, Kenichi, Horike, Shin‐ichi, Inoue, Hiroshi, Yano, Seiji, Kumar, Sharad, Kitajima, Shunsuke, Ajioka, Itsuki, Takahashi, Chiaki
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.10.2021
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background and Aims Synthetic cyclin‐dependent kinase (CDK) 4/6 inhibitors exert antitumor effects by forcing RB1 in unphosphorylated status, causing not only cell cycle arrest but also cellular senescence, apoptosis, and increased immunogenicity. These agents currently have an indication in advanced breast cancers and are in clinical trials for many other solid tumors. HCC is one of promising targets of CDK4/6 inhibitors. RB family dysfunction is often associated with the initiation of HCC; however, this is revivable, as RB family members are not frequently mutated or deleted in this malignancy. Approach and Results Loss of all Rb family members in transformation related protein 53 (Trp53)−/− mouse liver resulted in liver tumor reminiscent of human HCC, and re‐expression of RB1 sensitized these tumors to a CDK4/6 inhibitor, palbociclib. Introduction of an unphosphorylatable form of RB1 (RB7LP) into multiple liver tumor cell lines induced effects similar to palbociclib. By screening for compounds that enhance the efficacy of RB7LP, we identified an I kappa B kinase (IKK)β inhibitor Bay 11‐7082. Consistently, RB7LP expression and treatment with palbociclib enhanced IKKα/β phosphorylation and NF‐κB activation. Combination therapy using palbociclib with Bay 11‐7082 was significantly more effective in hepatoblastoma and HCC treatment than single administration. Moreover, blockade of IKK–NF‐κB or AKT pathway enhanced effects of palbociclib on RB1‐intact KRAS Kirsten rat sarcoma viral oncogene homolog mutated lung and colon cancers. Conclusions In conclusion, CDK4/6 inhibitors have a potential to treat a wide variety of RB1‐intact cancers including HCC when combined with an appropriate kinase inhibitor.
AbstractList BACKGROUND AND AIMSSynthetic cyclin-dependent kinase (CDK) 4/6 inhibitors exert antitumor effects by forcing RB1 in unphosphorylated status, causing not only cell cycle arrest but also cellular senescence, apoptosis, and increased immunogenicity. These agents currently have an indication in advanced breast cancers and are in clinical trials for many other solid tumors. HCC is one of promising targets of CDK4/6 inhibitors. RB family dysfunction is often associated with the initiation of HCC; however, this is revivable, as RB family members are not frequently mutated or deleted in this malignancy. APPROACH AND RESULTSLoss of all Rb family members in transformation related protein 53 (Trp53)-/- mouse liver resulted in liver tumor reminiscent of human HCC, and re-expression of RB1 sensitized these tumors to a CDK4/6 inhibitor, palbociclib. Introduction of an unphosphorylatable form of RB1 (RB7LP) into multiple liver tumor cell lines induced effects similar to palbociclib. By screening for compounds that enhance the efficacy of RB7LP, we identified an I kappa B kinase (IKK)β inhibitor Bay 11-7082. Consistently, RB7LP expression and treatment with palbociclib enhanced IKKα/β phosphorylation and NF-κB activation. Combination therapy using palbociclib with Bay 11-7082 was significantly more effective in hepatoblastoma and HCC treatment than single administration. Moreover, blockade of IKK-NF-κB or AKT pathway enhanced effects of palbociclib on RB1-intact KRAS Kirsten rat sarcoma viral oncogene homolog mutated lung and colon cancers. CONCLUSIONSIn conclusion, CDK4/6 inhibitors have a potential to treat a wide variety of RB1-intact cancers including HCC when combined with an appropriate kinase inhibitor.
Background and Aims Synthetic cyclin‐dependent kinase (CDK) 4/6 inhibitors exert antitumor effects by forcing RB1 in unphosphorylated status, causing not only cell cycle arrest but also cellular senescence, apoptosis, and increased immunogenicity. These agents currently have an indication in advanced breast cancers and are in clinical trials for many other solid tumors. HCC is one of promising targets of CDK4/6 inhibitors. RB family dysfunction is often associated with the initiation of HCC; however, this is revivable, as RB family members are not frequently mutated or deleted in this malignancy. Approach and Results Loss of all Rb family members in transformation related protein 53 (Trp53)−/− mouse liver resulted in liver tumor reminiscent of human HCC, and re‐expression of RB1 sensitized these tumors to a CDK4/6 inhibitor, palbociclib. Introduction of an unphosphorylatable form of RB1 (RB7LP) into multiple liver tumor cell lines induced effects similar to palbociclib. By screening for compounds that enhance the efficacy of RB7LP, we identified an I kappa B kinase (IKK)β inhibitor Bay 11‐7082. Consistently, RB7LP expression and treatment with palbociclib enhanced IKKα/β phosphorylation and NF‐κB activation. Combination therapy using palbociclib with Bay 11‐7082 was significantly more effective in hepatoblastoma and HCC treatment than single administration. Moreover, blockade of IKK–NF‐κB or AKT pathway enhanced effects of palbociclib on RB1‐intact KRAS Kirsten rat sarcoma viral oncogene homolog mutated lung and colon cancers. Conclusions In conclusion, CDK4/6 inhibitors have a potential to treat a wide variety of RB1‐intact cancers including HCC when combined with an appropriate kinase inhibitor.
Background and AimsSynthetic cyclin‐dependent kinase (CDK) 4/6 inhibitors exert antitumor effects by forcing RB1 in unphosphorylated status, causing not only cell cycle arrest but also cellular senescence, apoptosis, and increased immunogenicity. These agents currently have an indication in advanced breast cancers and are in clinical trials for many other solid tumors. HCC is one of promising targets of CDK4/6 inhibitors. RB family dysfunction is often associated with the initiation of HCC; however, this is revivable, as RB family members are not frequently mutated or deleted in this malignancy.Approach and ResultsLoss of all Rb family members in transformation related protein 53 (Trp53)−/− mouse liver resulted in liver tumor reminiscent of human HCC, and re‐expression of RB1 sensitized these tumors to a CDK4/6 inhibitor, palbociclib. Introduction of an unphosphorylatable form of RB1 (RB7LP) into multiple liver tumor cell lines induced effects similar to palbociclib. By screening for compounds that enhance the efficacy of RB7LP, we identified an I kappa B kinase (IKK)β inhibitor Bay 11‐7082. Consistently, RB7LP expression and treatment with palbociclib enhanced IKKα/β phosphorylation and NF‐κB activation. Combination therapy using palbociclib with Bay 11‐7082 was significantly more effective in hepatoblastoma and HCC treatment than single administration. Moreover, blockade of IKK–NF‐κB or AKT pathway enhanced effects of palbociclib on RB1‐intact KRAS Kirsten rat sarcoma viral oncogene homolog mutated lung and colon cancers.ConclusionsIn conclusion, CDK4/6 inhibitors have a potential to treat a wide variety of RB1‐intact cancers including HCC when combined with an appropriate kinase inhibitor.
Synthetic cyclin-dependent kinase (CDK) 4/6 inhibitors exert antitumor effects by forcing RB1 in unphosphorylated status, causing not only cell cycle arrest but also cellular senescence, apoptosis, and increased immunogenicity. These agents currently have an indication in advanced breast cancers and are in clinical trials for many other solid tumors. HCC is one of promising targets of CDK4/6 inhibitors. RB family dysfunction is often associated with the initiation of HCC; however, this is revivable, as RB family members are not frequently mutated or deleted in this malignancy. Loss of all Rb family members in transformation related protein 53 (Trp53) mouse liver resulted in liver tumor reminiscent of human HCC, and re-expression of RB1 sensitized these tumors to a CDK4/6 inhibitor, palbociclib. Introduction of an unphosphorylatable form of RB1 (RB7LP) into multiple liver tumor cell lines induced effects similar to palbociclib. By screening for compounds that enhance the efficacy of RB7LP, we identified an I kappa B kinase (IKK)β inhibitor Bay 11-7082. Consistently, RB7LP expression and treatment with palbociclib enhanced IKKα/β phosphorylation and NF-κB activation. Combination therapy using palbociclib with Bay 11-7082 was significantly more effective in hepatoblastoma and HCC treatment than single administration. Moreover, blockade of IKK-NF-κB or AKT pathway enhanced effects of palbociclib on RB1-intact KRAS Kirsten rat sarcoma viral oncogene homolog mutated lung and colon cancers. In conclusion, CDK4/6 inhibitors have a potential to treat a wide variety of RB1-intact cancers including HCC when combined with an appropriate kinase inhibitor.
Author Matsuda, Fumio
Inoue, Hiroshi
Sheng, Jindan
Yamamura, Minako
Takahashi, Chiaki
Linn, Paing
Harada, Kenichi
Okahashi, Nobuyuki
Kohno, Susumu
Kumar, Sharad
Yano, Seiji
Teranishi, Kana
Kitajima, Shunsuke
Ajioka, Itsuki
Okada, Nobuhiro
Shimizu, Hiroshi
Horike, Shin‐ichi
Nagatani, Naoko
Author_xml – sequence: 1
  givenname: Jindan
  surname: Sheng
  fullname: Sheng, Jindan
  organization: Kanazawa University
– sequence: 2
  givenname: Susumu
  surname: Kohno
  fullname: Kohno, Susumu
  email: skohno@staff.kanazawa-u.ac.jp
  organization: Kanazawa University
– sequence: 3
  givenname: Nobuhiro
  surname: Okada
  fullname: Okada, Nobuhiro
  organization: Okayama University
– sequence: 4
  givenname: Nobuyuki
  surname: Okahashi
  fullname: Okahashi, Nobuyuki
  organization: Osaka University
– sequence: 5
  givenname: Kana
  surname: Teranishi
  fullname: Teranishi, Kana
  organization: Kanazawa University
– sequence: 6
  givenname: Fumio
  surname: Matsuda
  fullname: Matsuda, Fumio
  organization: Osaka University
– sequence: 7
  givenname: Hiroshi
  surname: Shimizu
  fullname: Shimizu, Hiroshi
  organization: Osaka University
– sequence: 8
  givenname: Paing
  surname: Linn
  fullname: Linn, Paing
  organization: Kanazawa University
– sequence: 9
  givenname: Naoko
  surname: Nagatani
  fullname: Nagatani, Naoko
  organization: Kanazawa University
– sequence: 10
  givenname: Minako
  surname: Yamamura
  fullname: Yamamura, Minako
  organization: Kanazawa University
– sequence: 11
  givenname: Kenichi
  surname: Harada
  fullname: Harada, Kenichi
  organization: Kanazawa University
– sequence: 12
  givenname: Shin‐ichi
  surname: Horike
  fullname: Horike, Shin‐ichi
  organization: Kanazawa University
– sequence: 13
  givenname: Hiroshi
  surname: Inoue
  fullname: Inoue, Hiroshi
  organization: Kanazawa University
– sequence: 14
  givenname: Seiji
  surname: Yano
  fullname: Yano, Seiji
  organization: Kanazawa University
– sequence: 15
  givenname: Sharad
  surname: Kumar
  fullname: Kumar, Sharad
  organization: University of South Australia
– sequence: 16
  givenname: Shunsuke
  surname: Kitajima
  fullname: Kitajima, Shunsuke
  organization: Harvard Medical School
– sequence: 17
  givenname: Itsuki
  surname: Ajioka
  fullname: Ajioka, Itsuki
  organization: Kanagawa Institute of Industrial Science and Technology
– sequence: 18
  givenname: Chiaki
  orcidid: 0000-0003-3390-9563
  surname: Takahashi
  fullname: Takahashi, Chiaki
  email: skohno@staff.kanazawa-u.ac.jp, chtakaha@staff.kanazawa-u.ac.jp
  organization: Kanazawa University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33931882$$D View this record in MEDLINE/PubMed
BookMark eNp10U-L1DAYBvAgK-7s6sEvIAEv7qE7-dO06VHG1RlcUGTEY0nTN0yWNqlJisxtPoLgN9xPshln9SB4eiH88iQvzwU6c94BQi8puaaEsOUOpmtOZc2eoAUVrC44F-QMLQirSdFQ3pyjixjvCCFNyeQzdM55k71kC3TYBlBpBJewN_gLJOt8N6iY_KgwvT_82rikdMJrmFTyGoZhHlTAKxV0ltl8s2mHV3s9WHd_-PkOJnD9Me2jdSoCLpcV3rid7Wzy-Zofu3yerHd4u4Ogpv1z9NSoIcKLx3mJvr6_2a7Wxe2nD5vV29tCc8FZoWmvGatIL7Q0xvTCCAJKGtA1l0ZSQqXuSKVL3phKUMlYI_JkVIveqIbxS_TmlDsF_32GmNrRxuM-yoGfY8sEI1KIipSZvv6H3vk5uPy7rGrRlPm1Y-DVSengYwxg2inYUYV9S0l7rKXNtbS_a8n21WPi3I3Q_5V_eshgeQI_7AD7_ye165vPp8gHu8iaiA
CitedBy_id crossref_primary_10_1038_s41416_024_02719_2
crossref_primary_10_1080_14737159_2022_2154658
crossref_primary_10_3389_fonc_2021_795548
crossref_primary_10_3389_fonc_2021_649093
crossref_primary_10_1186_s12885_022_10475_w
crossref_primary_10_1016_j_celrep_2024_113924
crossref_primary_10_1007_s13402_022_00714_4
crossref_primary_10_1016_j_biopha_2023_115002
crossref_primary_10_1186_s13287_023_03316_5
crossref_primary_10_1080_14728222_2021_1976142
crossref_primary_10_3390_cells12010132
crossref_primary_10_1111_cas_16122
crossref_primary_10_3390_cancers14102430
crossref_primary_10_5702_massspec_S23_53
crossref_primary_10_1186_s13046_023_02615_2
crossref_primary_10_3390_ijms24043436
crossref_primary_10_1039_D2NR01469F
crossref_primary_10_3389_fimmu_2022_974377
crossref_primary_10_1016_j_pharmthera_2022_108229
crossref_primary_10_1038_s41388_023_02861_w
crossref_primary_10_1155_2021_5555590
Cites_doi 10.1016/j.trecan.2016.11.006
10.1038/71600
10.1016/j.jbiosc.2015.04.003
10.1136/gutjnl-2016-312268
10.1053/jhep.2003.50112
10.1158/2159-8290.CD-18-0264
10.1158/1078-0432.CCR-18-0685
10.1074/jbc.M605271200
10.1084/jem.20110198
10.1128/MCB.17.10.5771
10.1002/art.22655
10.1186/s13046-018-0741-3
10.1016/j.molcel.2019.01.004
10.1002/ijc.32020
10.1016/j.jhep.2020.01.019
10.1158/1541-7786.MCR-07-0098
10.1073/pnas.1008322108
10.1038/386177a0
10.1523/JNEUROSCI.1038-15.2016
10.1038/nature23465
10.1038/onc.2010.448
10.1038/sj.onc.1209547
10.1073/pnas.96.20.11217
10.1038/nrclinonc.2016.26
10.18632/oncotarget.14681
ContentType Journal Article
Copyright 2021 by the American Association for the Study of Liver Diseases.
Copyright_xml – notice: 2021 by the American Association for the Study of Liver Diseases.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7T5
7TM
7TO
7U9
H94
K9.
7X8
DOI 10.1002/hep.31872
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Immunology Abstracts
Nucleic Acids Abstracts
Oncogenes and Growth Factors Abstracts
Virology and AIDS Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Virology and AIDS Abstracts
Oncogenes and Growth Factors Abstracts
Nucleic Acids Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

AIDS and Cancer Research Abstracts
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1527-3350
EndPage 1993
ExternalDocumentID 10_1002_hep_31872
33931882
HEP31872
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Grant‐in‐Aid for Scientific Research
  funderid: 15H01487; 17H03576; 17H05615; 17K19586; 19K22555
– fundername: Funding Program for Next Generation World‐Leading Researchers
  funderid: LS049
GroupedDBID ---
--K
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
186
1B1
1CY
1L6
1OB
1OC
1ZS
1~5
24P
31~
33P
3O-
3SF
3WU
4.4
4G.
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5RE
5VS
7-5
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAEDT
AAESR
AAEVG
AAHHS
AALRI
AAONW
AAQFI
AAQQT
AAQXK
AASGY
AAXRX
AAXUO
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABLJU
ABMAC
ABOCM
ABPVW
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADEOM
ADIZJ
ADKYN
ADMGS
ADMUD
ADOZA
ADXAS
ADZMN
ADZOD
AECAP
AEEZP
AEIMD
AENEX
AEQDE
AEUQT
AFBPY
AFFNX
AFGKR
AFPWT
AFUWQ
AFZJQ
AHMBA
AIACR
AIURR
AIWBW
AJAOE
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BAWUL
BDRZF
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DIK
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
E3Z
EBS
EJD
F00
F01
F04
F5P
FD8
FDB
FEDTE
FGOYB
FUBAC
G-S
G.N
GNP
GODZA
H.X
HBH
HF~
HHY
HHZ
HVGLF
HZ~
IHE
IX1
J0M
J5H
JPC
KBYEO
KQQ
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
M41
M65
MJL
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N4W
N9A
NF~
NNB
NQ-
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
QRW
R.K
R2-
RGB
RIG
RIWAO
RJQFR
ROL
RPZ
RWI
RX1
RYL
SEW
SSZ
SUPJJ
TEORI
UB1
V2E
V9Y
W2D
W8V
W99
WBKPD
WH7
WHWMO
WIB
WIH
WIJ
WIK
WIN
WJL
WOHZO
WQJ
WRC
WUP
WVDHM
WXI
X7M
XG1
XV2
ZGI
ZXP
ZZTAW
~IA
~WT
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
ACLDA
ACRPL
ACYXJ
ADNMO
CITATION
7T5
7TM
7TO
7U9
H94
K9.
7X8
ID FETCH-LOGICAL-c3532-c1dc2260d5c8fffd5f50ea8fec738f81018cb06c439f6518229565121c5dfa923
IEDL.DBID DR2
ISSN 0270-9139
IngestDate Wed Dec 04 08:50:37 EST 2024
Thu Oct 10 20:15:09 EDT 2024
Fri Dec 06 07:08:00 EST 2024
Sat Sep 28 08:23:28 EDT 2024
Sat Aug 24 00:59:44 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 4
Language English
License 2021 by the American Association for the Study of Liver Diseases.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3532-c1dc2260d5c8fffd5f50ea8fec738f81018cb06c439f6518229565121c5dfa923
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0003-3390-9563
PMID 33931882
PQID 2575941012
PQPubID 996352
PageCount 23
ParticipantIDs proquest_miscellaneous_2520855604
proquest_journals_2575941012
crossref_primary_10_1002_hep_31872
pubmed_primary_33931882
wiley_primary_10_1002_hep_31872_HEP31872
PublicationCentury 2000
PublicationDate October 2021
2021-10-00
20211001
PublicationDateYYYYMMDD 2021-10-01
PublicationDate_xml – month: 10
  year: 2021
  text: October 2021
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Hoboken
PublicationTitle Hepatology (Baltimore, Md.)
PublicationTitleAlternate Hepatology
PublicationYear 2021
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2019; 8
2017; 8
2019; 9
2019; 73
2017; 3
2000; 6
2017; 66
2015; 120
2011; 30
2003; 37
2020; 12
2007; 56
2016; 36
2019; 145
2016; 13
2001; 21
2017; 548
2018; 8
2011; 208
2011; 108
2014; 3
2020; 72
2006; 25
1997; 386
2019; 25
1997; 17
2007; 5
1999; 96
2007; 3
2006; 281
2018; 37
1994; 54
(hep31872-bib-0024-20241017) 2019; 8
(hep31872-bib-0014-20241017) 2017; 3
(hep31872-bib-0010-20241017) 2014; 3
(hep31872-bib-0018-20241017) 2011; 30
(hep31872-bib-0032-20241017) 2007; 56
(hep31872-bib-0009-20241017) 2019; 73
(hep31872-bib-0022-20241017) 2011; 208
(hep31872-bib-0021-20241017) 2006; 281
(hep31872-bib-0028-20241017) 1994; 54
(hep31872-bib-0019-20241017) 2015; 120
(hep31872-bib-0004-20241017) 2007; 5
(hep31872-bib-0029-20241017) 1999; 96
(hep31872-bib-0001-20241017) 2018; 8
(hep31872-bib-0020-20241017) 2011; 108
(hep31872-bib-0027-20241017) 2018; 8
(hep31872-bib-0025-20241017) 2018; 37
(hep31872-bib-0030-20241017) 2020; 72
(hep31872-bib-0006-20241017) 2001; 21
(hep31872-bib-0007-20241017) 2003; 37
(hep31872-bib-0008-20241017) 2006; 25
(hep31872-bib-0023-20241017) 2019; 145
(hep31872-bib-0033-20241017) 2016; 36
(hep31872-bib-0011-20241017) 2017; 548
(hep31872-bib-0013-20241017) 2019; 25
(hep31872-bib-0016-20241017) 1997; 386
(hep31872-bib-0015-20241017) 1997; 17
(hep31872-bib-0012-20241017) 2017; 66
(hep31872-bib-0005-20241017) 2000; 6
(hep31872-bib-0026-20241017) 2016; 13
(hep31872-bib-0031-20241017) 2019; 9
(hep31872-bib-0003-20241017) 2007; 3
(hep31872-bib-0017-20241017) 2017; 8
(hep31872-bib-0002-20241017) 2020; 12
References_xml – volume: 108
  start-page: 1531
  year: 2011
  end-page: 1536
  article-title: A hyperactive piggyBac transposase for mammalian applications
  publication-title: Proc Natl Acad Sci U S A
– volume: 9
  year: 2019
  article-title: Mechanisms of resistance to CDK4/6 inhibitors: potential implications and biomarkers for clinical practice
  publication-title: Front Oncol
– volume: 73
  start-page: 985
  year: 2019
  end-page: 1000.e6
  article-title: A code of mono‐phosphorylation modulates the function of RB
  publication-title: Mol Cell
– volume: 208
  start-page: 1963
  year: 2011
  end-page: 1976
  article-title: Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway
  publication-title: J Exp Med
– volume: 25
  start-page: 3778
  year: 2006
  end-page: 3786
  article-title: Genetics of hepatocellular tumors
  publication-title: Oncogene
– volume: 120
  start-page: 725
  year: 2015
  end-page: 731
  article-title: Metabolic characterization of cultured mammalian cells by mass balance analysis, tracer labeling experiments and computer‐aided simulations
  publication-title: J Biosci Bioeng
– volume: 36
  start-page: 125
  year: 2016
  end-page: 141
  article-title: Enhanced store‐operated calcium entry leads to striatal synaptic loss in a Huntington's disease mouse model
  publication-title: J Neurosci
– volume: 8
  year: 2018
  article-title: CDK 4/6 inhibitors as single agent in advanced solid tumors
  publication-title: Front Oncol
– volume: 548
  start-page: 471
  year: 2017
  end-page: 475
  article-title: CDK4/6 inhibition triggers anti‐tumour immunity
  publication-title: Nature
– volume: 281
  start-page: 38098
  year: 2006
  end-page: 38108
  article-title: Nucleocytoplasmic shuttling of the retinoblastoma tumor suppressor protein via Cdk phosphorylation‐dependent nuclear export
  publication-title: J Biol Chem
– volume: 145
  start-page: 1179
  year: 2019
  end-page: 1188
  article-title: Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: a review
  publication-title: Int J Cancer
– volume: 37
  start-page: 72
  year: 2018
  article-title: The anti‐tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells
  publication-title: J Exp Clin Cancer Res
– volume: 54
  start-page: 1812
  year: 1994
  end-page: 1817
  article-title: Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining
  publication-title: Cancer Res
– volume: 8
  start-page: 1390
  year: 2018
  end-page: 1403
  article-title: The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA‐3 trial
  publication-title: Cancer Discov
– volume: 5
  start-page: 1063
  year: 2007
  end-page: 1072
  article-title: Hepatitis B virus pre‐S2 mutant surface antigen induces degradation of cyclin‐dependent kinase inhibitor p27Kip1 through c‐Jun activation domain‐binding protein 1
  publication-title: Mol Cancer Res
– volume: 3
  start-page: 39
  year: 2017
  end-page: 55
  article-title: The strange case of CDK4/6 inhibitors: mechanisms, resistance, and combination strategies
  publication-title: Trends Cancer
– volume: 30
  start-page: 737
  year: 2011
  end-page: 750
  article-title: Reversion‐inducing cysteine‐rich protein with Kazal motifs interferes with epidermal growth factor receptor signaling
  publication-title: Oncogene
– volume: 37
  start-page: 534
  year: 2003
  end-page: 543
  article-title: Cyclins and cyclin‐dependent kinases: comparative study of hepatocellular carcinoma versus cirrhosis
  publication-title: Hepatology
– volume: 3
  year: 2014
  article-title: Cyclin D activates the Rb tumor suppressor by mono‐phosphorylation
  publication-title: eLife
– volume: 3
  start-page: 1335
  year: 2007
  end-page: 1347
  article-title: Hepatitis C virus induces E6AP‐dependent degradation of the retinoblastoma protein
  publication-title: PLoS Pathog
– volume: 8
  start-page: 13872
  year: 2017
  end-page: 13885
  article-title: MicroRNA‐140 mediates RB tumor suppressor function to control stem cell‐like activity through interleukin‐6
  publication-title: Oncotarget
– volume: 25
  start-page: 390
  year: 2019
  end-page: 402
  article-title: CDK4/6 inhibitor as a novel therapeutic approach for advanced bladder cancer independently of RB1 status
  publication-title: Clin Cancer Res
– volume: 72
  start-page: 990
  year: 2020
  end-page: 1002
  article-title: The landscape of gene mutations in cirrhosis and hepatocellular carcinoma
  publication-title: J Hepatol
– volume: 66
  start-page: 1286
  year: 2017
  end-page: 1296
  article-title: Palbociclib (PD‐0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma
  publication-title: Gut
– volume: 17
  start-page: 5771
  year: 1997
  end-page: 5783
  article-title: Dual mechanisms for the inhibition of E2F binding to RB by cyclin‐dependent kinase‐mediated RB phosphorylation
  publication-title: Mol Cell Biol
– volume: 21
  start-page: 657
  year: 2001
  end-page: 662
  article-title: Enhanced expression of cyclin E and cyclin A in human hepatocellular carcinomas
  publication-title: Anticancer Res
– volume: 12
  start-page: 45
  year: 2020
  end-page: 56
  article-title: Fulvestrant in combination with CDK4/6 inhibitors for HER2‐ metastatic breast cancers: current perspectives
  publication-title: Breast Cancer
– volume: 8
  year: 2019
  article-title: Updates on the CDK4/6 inhibitory strategy and combinations in breast cancer
  publication-title: Cells
– volume: 13
  start-page: 417
  year: 2016
  end-page: 430
  article-title: Treating cancer with selective CDK4/6 inhibitors
  publication-title: Nat Rev Clin Oncol
– volume: 96
  start-page: 11217
  year: 1999
  end-page: 11222
  article-title: Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response‐like element
  publication-title: Proc Natl Acad Sci U S A
– volume: 56
  start-page: 2255
  year: 2007
  end-page: 2266
  article-title: Antigen‐specific suppression of established arthritis in mice by dendritic cells deficient in NF‐kappaB
  publication-title: Arthritis Rheum
– volume: 6
  start-page: 96
  year: 2000
  end-page: 99
  article-title: Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin‐repeat protein overexpressed in hepatomas
  publication-title: Nat Med
– volume: 386
  start-page: 177
  year: 1997
  end-page: 181
  article-title: Ras signalling linked to the cell‐cycle machinery by the retinoblastoma protein
  publication-title: Nature
– volume: 3
  start-page: 39
  year: 2017
  ident: hep31872-bib-0014-20241017
  article-title: The strange case of CDK4/6 inhibitors: mechanisms, resistance, and combination strategies
  publication-title: Trends Cancer
  doi: 10.1016/j.trecan.2016.11.006
– volume: 6
  start-page: 96
  year: 2000
  ident: hep31872-bib-0005-20241017
  article-title: Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin‐repeat protein overexpressed in hepatomas
  publication-title: Nat Med
  doi: 10.1038/71600
– volume: 9
  year: 2019
  ident: hep31872-bib-0031-20241017
  article-title: Mechanisms of resistance to CDK4/6 inhibitors: potential implications and biomarkers for clinical practice
  publication-title: Front Oncol
– volume: 3
  start-page: 1335
  year: 2007
  ident: hep31872-bib-0003-20241017
  article-title: Hepatitis C virus induces E6AP‐dependent degradation of the retinoblastoma protein
  publication-title: PLoS Pathog
– volume: 21
  start-page: 657
  year: 2001
  ident: hep31872-bib-0006-20241017
  article-title: Enhanced expression of cyclin E and cyclin A in human hepatocellular carcinomas
  publication-title: Anticancer Res
– volume: 120
  start-page: 725
  year: 2015
  ident: hep31872-bib-0019-20241017
  article-title: Metabolic characterization of cultured mammalian cells by mass balance analysis, tracer labeling experiments and computer‐aided simulations
  publication-title: J Biosci Bioeng
  doi: 10.1016/j.jbiosc.2015.04.003
– volume: 66
  start-page: 1286
  year: 2017
  ident: hep31872-bib-0012-20241017
  article-title: Palbociclib (PD‐0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma
  publication-title: Gut
  doi: 10.1136/gutjnl-2016-312268
– volume: 8
  year: 2018
  ident: hep31872-bib-0001-20241017
  article-title: CDK 4/6 inhibitors as single agent in advanced solid tumors
  publication-title: Front Oncol
– volume: 37
  start-page: 534
  year: 2003
  ident: hep31872-bib-0007-20241017
  article-title: Cyclins and cyclin‐dependent kinases: comparative study of hepatocellular carcinoma versus cirrhosis
  publication-title: Hepatology
  doi: 10.1053/jhep.2003.50112
– volume: 8
  start-page: 1390
  year: 2018
  ident: hep31872-bib-0027-20241017
  article-title: The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA‐3 trial
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-18-0264
– volume: 12
  start-page: 45
  year: 2020
  ident: hep31872-bib-0002-20241017
  article-title: Fulvestrant in combination with CDK4/6 inhibitors for HER2‐ metastatic breast cancers: current perspectives
  publication-title: Breast Cancer
– volume: 54
  start-page: 1812
  year: 1994
  ident: hep31872-bib-0028-20241017
  article-title: Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining
  publication-title: Cancer Res
– volume: 25
  start-page: 390
  year: 2019
  ident: hep31872-bib-0013-20241017
  article-title: CDK4/6 inhibitor as a novel therapeutic approach for advanced bladder cancer independently of RB1 status
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-18-0685
– volume: 281
  start-page: 38098
  year: 2006
  ident: hep31872-bib-0021-20241017
  article-title: Nucleocytoplasmic shuttling of the retinoblastoma tumor suppressor protein via Cdk phosphorylation‐dependent nuclear export
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M605271200
– volume: 208
  start-page: 1963
  year: 2011
  ident: hep31872-bib-0022-20241017
  article-title: Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway
  publication-title: J Exp Med
  doi: 10.1084/jem.20110198
– volume: 17
  start-page: 5771
  year: 1997
  ident: hep31872-bib-0015-20241017
  article-title: Dual mechanisms for the inhibition of E2F binding to RB by cyclin‐dependent kinase‐mediated RB phosphorylation
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.17.10.5771
– volume: 56
  start-page: 2255
  year: 2007
  ident: hep31872-bib-0032-20241017
  article-title: Antigen‐specific suppression of established arthritis in mice by dendritic cells deficient in NF‐kappaB
  publication-title: Arthritis Rheum
  doi: 10.1002/art.22655
– volume: 37
  start-page: 72
  year: 2018
  ident: hep31872-bib-0025-20241017
  article-title: The anti‐tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells
  publication-title: J Exp Clin Cancer Res
  doi: 10.1186/s13046-018-0741-3
– volume: 73
  start-page: 985
  year: 2019
  ident: hep31872-bib-0009-20241017
  article-title: A code of mono‐phosphorylation modulates the function of RB
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2019.01.004
– volume: 145
  start-page: 1179
  year: 2019
  ident: hep31872-bib-0023-20241017
  article-title: Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: a review
  publication-title: Int J Cancer
  doi: 10.1002/ijc.32020
– volume: 72
  start-page: 990
  year: 2020
  ident: hep31872-bib-0030-20241017
  article-title: The landscape of gene mutations in cirrhosis and hepatocellular carcinoma
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2020.01.019
– volume: 5
  start-page: 1063
  year: 2007
  ident: hep31872-bib-0004-20241017
  article-title: Hepatitis B virus pre‐S2 mutant surface antigen induces degradation of cyclin‐dependent kinase inhibitor p27Kip1 through c‐Jun activation domain‐binding protein 1
  publication-title: Mol Cancer Res
  doi: 10.1158/1541-7786.MCR-07-0098
– volume: 108
  start-page: 1531
  year: 2011
  ident: hep31872-bib-0020-20241017
  article-title: A hyperactive piggyBac transposase for mammalian applications
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1008322108
– volume: 386
  start-page: 177
  year: 1997
  ident: hep31872-bib-0016-20241017
  article-title: Ras signalling linked to the cell‐cycle machinery by the retinoblastoma protein
  publication-title: Nature
  doi: 10.1038/386177a0
– volume: 36
  start-page: 125
  year: 2016
  ident: hep31872-bib-0033-20241017
  article-title: Enhanced store‐operated calcium entry leads to striatal synaptic loss in a Huntington's disease mouse model
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.1038-15.2016
– volume: 548
  start-page: 471
  year: 2017
  ident: hep31872-bib-0011-20241017
  article-title: CDK4/6 inhibition triggers anti‐tumour immunity
  publication-title: Nature
  doi: 10.1038/nature23465
– volume: 30
  start-page: 737
  year: 2011
  ident: hep31872-bib-0018-20241017
  article-title: Reversion‐inducing cysteine‐rich protein with Kazal motifs interferes with epidermal growth factor receptor signaling
  publication-title: Oncogene
  doi: 10.1038/onc.2010.448
– volume: 25
  start-page: 3778
  year: 2006
  ident: hep31872-bib-0008-20241017
  article-title: Genetics of hepatocellular tumors
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1209547
– volume: 96
  start-page: 11217
  year: 1999
  ident: hep31872-bib-0029-20241017
  article-title: Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response‐like element
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.96.20.11217
– volume: 13
  start-page: 417
  year: 2016
  ident: hep31872-bib-0026-20241017
  article-title: Treating cancer with selective CDK4/6 inhibitors
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/nrclinonc.2016.26
– volume: 3
  year: 2014
  ident: hep31872-bib-0010-20241017
  article-title: Cyclin D activates the Rb tumor suppressor by mono‐phosphorylation
  publication-title: eLife
– volume: 8
  start-page: 13872
  year: 2017
  ident: hep31872-bib-0017-20241017
  article-title: MicroRNA‐140 mediates RB tumor suppressor function to control stem cell‐like activity through interleukin‐6
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.14681
– volume: 8
  year: 2019
  ident: hep31872-bib-0024-20241017
  article-title: Updates on the CDK4/6 inhibitory strategy and combinations in breast cancer
  publication-title: Cells
SSID ssj0009428
Score 2.5315795
Snippet Background and Aims Synthetic cyclin‐dependent kinase (CDK) 4/6 inhibitors exert antitumor effects by forcing RB1 in unphosphorylated status, causing not only...
Synthetic cyclin-dependent kinase (CDK) 4/6 inhibitors exert antitumor effects by forcing RB1 in unphosphorylated status, causing not only cell cycle arrest...
Background and AimsSynthetic cyclin‐dependent kinase (CDK) 4/6 inhibitors exert antitumor effects by forcing RB1 in unphosphorylated status, causing not only...
BACKGROUND AND AIMSSynthetic cyclin-dependent kinase (CDK) 4/6 inhibitors exert antitumor effects by forcing RB1 in unphosphorylated status, causing not only...
SourceID proquest
crossref
pubmed
wiley
SourceType Aggregation Database
Index Database
Publisher
StartPage 1971
SubjectTerms AKT protein
Aminopyridines - pharmacology
Aminopyridines - therapeutic use
Animals
Antitumor activity
Apoptosis
Benzimidazoles - pharmacology
Benzimidazoles - therapeutic use
Breast cancer
Cancer
Carcinoma, Hepatocellular - drug therapy
Carcinoma, Hepatocellular - genetics
Cell cycle
Cell Proliferation - drug effects
Cell Proliferation - genetics
Cell Survival - drug effects
Clinical trials
Combination therapy
Cyclin-dependent kinase 4
Cyclin-Dependent Kinase 4 - antagonists & inhibitors
Cyclin-Dependent Kinase 6 - antagonists & inhibitors
Enzyme inhibitors
Hep G2 Cells
Hepatocellular carcinoma
Hepatocytes
Hepatology
Humans
IKK protein
Immunogenicity
In Vitro Techniques
Liver cancer
Liver Neoplasms - drug therapy
Liver Neoplasms - genetics
Liver Neoplasms, Experimental - drug therapy
Liver Neoplasms, Experimental - genetics
Malignancy
Mice
Neoplasm Transplantation
Phosphorylation
Piperazines - pharmacology
Piperazines - therapeutic use
Protein Kinase Inhibitors - pharmacology
Protein Kinase Inhibitors - therapeutic use
Purines - pharmacology
Purines - therapeutic use
Pyridines - pharmacology
Pyridines - therapeutic use
Retina
Retinoblastoma
Retinoblastoma Protein
Sarcoma
Senescence
Solid tumors
Tumor cell lines
Tumor Suppressor Protein p53 - genetics
Tumors
Xenopus Proteins
Title Treatment of Retinoblastoma 1–Intact Hepatocellular Carcinoma With Cyclin‐Dependent Kinase 4/6 Inhibitor Combination Therapy
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhep.31872
https://www.ncbi.nlm.nih.gov/pubmed/33931882
https://www.proquest.com/docview/2575941012
https://search.proquest.com/docview/2520855604
Volume 74
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NSuRAEC7Eg3hx_V3HVWmXPXiJk6Q7MwmeZFRGFxeRET0shE6nmxnEZFl7DutpHkHwDX0SqzrJiIogewukf5Luqq6vu6u-AvghlDZJrDIP7WnmESGXJxMReAbNOxfayMRQ7PDZr07_UpxeR9czsN_EwlT8ENMDN9IMt16Tgsvsrv1CGjrUuGEP4i6tvwHvkjvf4cULdVQiXF5V3HX5dLucNKxCftie1nxti94BzNd41Rmc4y_wu_nUys_kZm9ssz11_4bF8T__ZREWaiDKDirJWYIZXSzD3Fl91b4Ck0Hjgs5Kwy4oMrrMEGrb8lay4GnyeFJYqSzroz2zJZ3_k0Mr61FuooLKXI3skPX-Uejl0-ThsE62a9nPUYGWk4l2h50Uw1GGSwpWK29xi-6khA0qooNVuDw-GvT6Xp2uwVM84qGnglwhmPPzSMXGmDwyka9lbLTq8tgQkRjKhN9RCIFMJwqIaR7RZBAGKspRJkK-BrNFWeh1YN04R1wmeZgnXHCTxzrHVqSveIaLtzIt-N5MXPqnYuVIK_7lMMWxTN1YtmCzmdK0Vsy7NKSEpIJIzVqwM32NKkXjJAtdjqkMJS5FKCha8LUShWkvnCfYeIy1d92Eftx92j86dw8bny_6DeZD8plxzoKbMGv_jvUWgh6bbTvpfgaFf_9n
link.rule.ids 314,780,784,1375,27924,27925,46294,46718
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1fT9swED8hJo29sA0YdOs2g_bAS2gSO20i7WVqQSlQNKEieJmixLHVaiKZwH3YnvoRkPiGfJLdOUkRIKRpb5HiP4l95_vZvvsdwBchlY5CmTloTzOHCLmcNBKeo9G8c6F0GmmKHR6ddOMzcXgRXCzB1yYWpuKHWBy4kWbY9ZoUnA6kO_esoROFO3Yv7OEC_ALV3SOHrsHpPXlUJGxmVdx3uXS_HDW8Qq7fWVR9aI2eQMyHiNWanIPX8KP52MrT5OfezGR78s8jHsf__Zs3sFpjUfatEp63sKSKNXg5qm_b12E-brzQWanZKQVHlxmibVNepsy7m98OC5NKw2I0aaakKwDyaWV9Sk9UUJnzqZmw_m-Kvryb3wzqfLuGHU0LNJ5MdLpsWEymGa4qWK28xF26FRQ2rrgONuDsYH_cj506Y4MjecB9R3q5RDzn5oEMtdZ5oANXpaFWssdDTVxiKBZuVyIK0t3AI7J5BJSe78kgR7Hw-TtYLspCbQHrhTlCs5T7ecQF13mocmwldSXPcP2WugU7zcwlvypijqSiYPYTHMvEjmUL2s2cJrVuXic-5SQVxGvWgu3Fa9QqGqe0UOWMylDuUkSDogWblSwseuE8wsZDrL1rZ_T57pN4_7t9eP_vRT_DSjweHSfHw5OjD_DKJxca6zvYhmVzNVMfEQOZ7JMV9b98SQOX
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5VRaq4AOW50IJBHLikm9hONhGnarerXUqrqtqKHpCixA_tCjWpwHuA0_4EJP5hf0lnnGSrgpAQt0ixncSex-d45huAt1IZm6WqDNCflgERcgVFJqPAonsX0tgis5Q7fHScTM7kh_P4fAPed7kwDT_E-ocbaYa316Tgl9r2b0hD5wY37FE6QPt7RyY8I-L80ekNd1QmfWFV3HaFdLycdbRCIe-vu952Rn8gzNuA1Xuc8X343L1rE2jyZW_pyj314zcax__8mAdwr0WibL8RnW3YMNVD2Dpqz9ofwWrWxaCz2rJTSo2uS8Tarr4oWHS1-jWtXKEcm6BDczUdAFBEKxtScaKK2nxauDkbfqfcy6vVz1Fbbdexw0WFrpPJfsKm1XxRok3BbvUF7tG9mLBZw3TwGM7GB7PhJGjrNQRKxIIHKtIK0VyoY5Vaa3Vs49AUqTVqIFJLTGIoFGGiEAPZJI6Iah7hZMQjFWsUCi6ewGZVV-YZsEGqEZgVgutMSGF1ajSOUoRKlGi9le3Bm27h8suGliNvCJh5jnOZ-7nswU63pHmrmd9yThVJJbGa9eD1-jbqFM1TUZl6SW2ociliQdmDp40orJ8iRIaDp9j7nV_Qvz8-nxyc-Ivn_970FWydjMb5x-nx4Qu4yyl-xgcO7sCm-7o0uwiAXPnSC_o1elgCRg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Treatment+of+Retinoblastoma+1%E2%80%93Intact+Hepatocellular+Carcinoma+With+Cyclin%E2%80%90Dependent+Kinase+4%2F6+Inhibitor+Combination+Therapy&rft.jtitle=Hepatology+%28Baltimore%2C+Md.%29&rft.au=Sheng%2C+Jindan&rft.au=Kohno%2C+Susumu&rft.au=Okada%2C+Nobuhiro&rft.au=Okahashi%2C+Nobuyuki&rft.date=2021-10-01&rft.pub=Wiley+Subscription+Services%2C+Inc&rft.issn=0270-9139&rft.eissn=1527-3350&rft.volume=74&rft.issue=4&rft.spage=1971&rft.epage=1993&rft_id=info:doi/10.1002%2Fhep.31872&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0270-9139&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0270-9139&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0270-9139&client=summon